As GLP-1 agonists and SGLT-2 inhibitors were only recently included in DM guidelines, we therefore anticipate a continuous reduction in DM-related mortality and hospitalization, in particular in patients with HF since the mortality reduction in those medications was mainly driven by a reduction in HF. The gene discussed is SLC5A2; the disease is diabetes mellitus.